North Hampshire Hospital Pioneers HIFU treatment
27 Jun 2017Richard Hindley discusses the benefits of HIFU and how North Hampshire Hospital have invested in the technology with the help of the Pelican Cancer Foundation and the North Hants Medical Fund.
Being at the forefront of technology and getting involved in the PROMIS trial has allowed Richard Hindley to offer his patients a greater choice of treatment for prostate cancer and the chance to make their own patient choices to suit their lifestyle.
Bringing you the latest news in BPH treatments
07 Jun 2017Urology Partners have always been at the forefront of new and emerging technologies which offer patients minimally invasive treatments to aid symptoms of Benign Prostatic Hyperplasia (BPH).
We currently offer Greenlight Laser and Urolift as the latest treatments for BPH. Our consultants have been part of trials for these treatments and have brought a significant number of patients to take part in these trials. Whilst Greenlight is now approved by NICE and Urolift continues in its pathway for NICE approval, the results from the ongoing trials of these treatments are proving successful.
Urologists in Trials Boost
01 Jun 2017
Coverage in the Basingstoke Gazette of the HIFU trials taking place at North Hampshire hospital led by Richard Hindley. The story also includes comments from a HIFU patient of Richard Hindley and his delight at the procedure outcomes for his prostate cancer
Basingstoke Observer reports on HIFU treatment at NHH
23 May 2017
Recent coverage from the Basingstoke Observer on HIFU treatment available at NHH.
Richard Hindley and the team at North Hampshire Hospital are investing a lot of time and skills into offering the latest treatments in Urology for patients. The results coming in are promising and continue to prove that HIFU is a treatment worth investing in and offers patients further choice on treatment options for prostate cancer.
Greenlight proves to be cost effective as treatment for BPH
22 Mar 2017
Neil Barber was part of the team behind this study which proves GreenLight XPS provides equivalent clinical outcomes with fewer adverse events and shorter recovery time in a more cost-effective manner compared with TURP as treatment for BPH.
How the latest prostate cancer research might affect you
08 Mar 2017January 2017 saw the results of the PROMIS trial and the evidence confirmed that the use of a Multi Parametric MRI (mpMRI) scan provides a more accurate diagnosis for men before any biopsy has to be considered.
This is great news for patients as currently in many hospitals the gold standard is to go straight to Trans Rectal ultrasound guided biopsy (TRUS) which are very hit and miss. As a result, in these hospitals many men without cancer undergo unnecessary biopsies, and some men are over diagnosed with prostate cancer which is actually clinically unimportant. Furthermore the study showed that half of all clinically important cancers (those which need treatment to stop the cancer growing) are missed with the TRUS biopsy method.
In addition there are potential side effects, including pain, bleeding and infection.
The results of the trial show that one quarter of men may not need to undergo unnecessary prostate biopsy if they undergo an MRI. MRI also detects 93% of important cancers (compared with 48% for TRUS prostate biopsies).
It is important for patients to know that with the prostate gland, cancer can be detected but it doesn’t always mean radical treatment is necessary. Clinically insignificant cancer can be present but is unlikely to cause any problems during a man’s lifetime.
mpMRI for Prostate Cancer diagnosis in Hampshire
15 Feb 2017
Following the news of the PROMIS trials results and the positive data for mpMRI becoming part of the pathway for Prostate Cancer diagnosis, Hampshire Hospitals are able to offer this diagnostic to NHS patients. Richard Hindley was involved in the trial and patients from Hampshire were part of the study. Urology Partners have used mpMRI for diagnosis for a number of years and are delighted to see it move forward under the NHS.